Full-year 2020 results Accelerating the scientific and commercial evolution; 2021 guidance shows continuing progress AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. With over half of Total Revenue coming from the fast-growing new medicines1, the Company leveraged its revenue growth to make further progress in profitability, while … Farxiga was the company's second‑highest‑selling product in 2020 (after Lisinopril). The 2020 sales reflect a mix of continued growth in type‑2‑diabetes prescriptions and a rapid expansion into heart‑failure indications in several markets. Pascal Soriot, Chief Executive Officer, commented: "We made encouraging headway in the quarter, despite the ongoing disruption from the COVID-19 pandemic. Highlights of the sales performance included further success in Oncology and an acceleration in the progress of Farxiga. Our pipeline also excelled, with Farxiga expanding its potential beyond diabetes and heart failure with ground … NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the challenges presented by the global pandemic," said Richard A. Gonzalez, chairman and chief executive … Farxiga, AstraZeneca's dapagliflozin product, is one of the largest global SGLT2 inhibitors and a core growth asset across type 2 diabetes, heart failure and chronic kidney disease. Global sales reached approximately $5.8 billion in 2023 and were on track for roughly $7 billion in 2024 based on AstraZeneca's reported quarterly performance. /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2020. $ in millions, except per… Selected top diabetes drugs by expected sales in 2020 and 2024 (in billion U.S. dollars) Select top diabetes drugs by sales in 2020 and 2024 forecast Annual Sales of Farxiga reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Otezla* generated $617 million of sales in the fourth quarter of 2020, and $2.2 billion for the full year. In the U.S. Farxiga sales grew by 6% to $569 million (2019: $537 million; 2018: $591 million), partly driven by a regulatory approval in May 2020 for the treatment of patients with heart failure with reduced ejection fraction (HFrEF) in both patients with and without T2D, based on the ground-breaking DAPA-HF trial. Annual Sales of Dapagliflozin reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. It also provides analysis of Dapagliflozin sales forecasts, along with factors driving its market. Dapagliflozin Drug Summary Dapagliflozin, marketed as Farxiga, is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used primarily for managing type 2 diabetes mellitus, heart failure, and chronic kidney disease. Farxiga 2020 U.S. PROMOTIONAL AUDIT REPORT Published July 2021 • 24 Pages The 5 Key Questions Addressed by this Report: How many physicians were reached by Farxiga through reportable promotional activity in 2020 and how does this compare to its peer set in the Heart Failure, Reduce Risk of Major Cardiovascular Events, and Type 2 Diabetes – SGLT2 markets? What promotional mix was leveraged … Invokana (canagliflozin, Janssen) Steglatro (ertugliflozin, Merck) FARXIGA's differentiation stems from its approval in multiple indications, notably HFrEF and CKD, beyond T2DM. Revenue Performance and Sales Trends AstraZeneca reported global sales of USD 4.3 billion for FARXIGA in 2022, a 25% increase from 2021 [4]. Product Sales grew by 15% (11% at CER) to $7,257m, driven primarily by the performances of new medicines across Oncology and BioPharmaceuticals, including Tagrisso and Farxiga. CEO Pascal Soriot remarked that "2022 has started strongly for AstraZeneca," adding "Farxiga achieved $1 billion revenue in the quarter and our oncology medicines delivered product sales growth of 18% [on a constant exchange rate basis], despite COVID-19 continuing to impact cancer diagnosis and … Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is segmented into drugs (Invokana, Jardiance, Farxiga/Forxiga, and Suglat) and Geography. The report offers the value (in USD) and volume (in Units) for the above segments. The Global Dapagliflozin Market was valued at USD 3.21 Billion in 2024 and is expected to reach USD 5.47 Billion by 2032, growing at a CAGR of 6.70% (2025-2032). In the decade since AstraZeneca's Farxiga first nabbed FDA approval to treat adults with type 2 diabetes, the drug has well surpassed blockbuster status, racking up additional indications and generating nearly $6 billion in sales in 2023. And it hasn't reached its peak yet, according to a … Annual pharmaceutical drug sales This is a list of annual sales of patented medications per pharmaceutical group. Because it derives from 10-K data, drugs that have passed loss of exclusivity (LOE) will cease to be on this list. Explore the FARXIGA Market trends, size, and future outlook with DelveInsight's latest report. Gain insights into Companies, emerging therapies, and forecasts Glenmark Pharmaceuticals Inc has received United States Food & Drug Administration (FDA) approval for Dapagliflozin tablets, 5 mg and 10 mg, the generic version of Farxiga tablets, 5 mg and 10 mg, of AstraZeneca AB. According to IQVIATM sales data for the 12 month period ending January 2020, the Farxiga tablets, 5mg and 10 mg market achieved annual sales of approximately $1.8 billion. Also … After delivering revenue growth of 67% year-over-year, Farxiga reached $1 billion in quarterly sales for the first time during the first three months of 2022. Dapagliflozin, as Farxiga, currently has FDA labeling for multiple indications: to improve glycemic control in adults with type 2 diabetes; to reduce the risk for hospitalization for heart failure … Much of the attention on AstraZeneca PLC in the past couple of years has focused on its blooming oncology franchise but its top earner is the pipeline-in-a-product Farxiga and sales of the SGLT2 inhibitor, which is approved type 2 diabetes, heart failure and chronic kidney disease, have soared again in the second quarter. Speaking to Scrip as the UK-headquartered giant unveiled its latest set … Dapagliflozin drug usage statistics for the United States (2014 – 2024). Statistics include drug synonyms and therapeutic classes, including: Dapagliflozin 2,3-butanediol Monohydrate, Dapagliflozin Propanediol, Dapagliflozin, Farxiga, Sodium-Glucose Cotransporter 2 Inhibitor. Total Revenue increased by 13% (9% at CER) in the year, driven by strong Farxiga performance, to $8,034m and represented 21% of overall Total Revenue (FY 2020: 27%). The comprehensive new report detailing FARXIGA's impact and projected growth in the myocardial infarction treatment landscape over the next decade is now available, offering crucial insights into … Read on for Farxiga (dapagliflozin) dosage information, including typical dosage, adjustments for health conditions, and what to do if you miss a dose. Cardiovascular, Renal and Metabolism (CVRM) sales were up 16% in the quarter. Farxiga sales were up 21% to $1.9 billion. Brilinta sales were $341 million, up 4%. Crestor sales were up 5% to $261 million. Respiratory & Immunology (R&I) sales in the quarter were up 27% to $2.1 billion. Symbicort sales were $684 million, up 31%. Fasenra sales were up 12% to $471 million. Breztri sales were up 29% … In 2019, the US FDA approved Farxiga to reduce the risk of hospitalisation for heart failure in adult patients with T2D and established cardiovascular disease or multiple cardiovascular risk factors. AstraZeneca has started 2020 strongly, with the FDA granting a fast review for its big-selling Farxiga in heart failure and a key drug approval in China. Prescription medicine sales data for Forxiga compiled from GlobalData's pharmaceutical product revenue figures on PMLiVE's Top Pharma List. DelveInsight's FARXIGA Market report covers size, trends, competitive landscape, and future outlook. Stay updated on the latest developments and forecasts. FARXIGA® (dapagliflozin), a medication for people with chronic kidney disease (CKD), heart failure, and type 2 diabetes. AstraZeneca has generated over $20.9 billion in sales revenue from Farxiga since its launch in 2014. Revenues obtained by AstraZeneca through Farxiga sales are nearly 30 times the median cost for research and development of a new drug estimated by experts. While at the National Association of Chain Drug Stores (NACDS) TSE 2025 Meeting, IQVIA reviewed the chart comparing five drugs (Eliquis, Xarelto, Jardiance, Farxiga, Januvia) over multiple years … AstraZeneca's product, Farxiga (dapagliflozin), was first approved by the USFDA in 2014 [24]. Although AstraZeneca's Farxiga is protected by a patent until 2025 and the company successfully defended its patent against a generic challenge in 2021 [25], generic dapagliflozin is now available in the United States. A case in point is Farxiga dapagliflozin from AstraZeneca plc (LSE:AZN; NASDAQ:AZN), which reported 2022 sales of nearly $4.4 billion for the therapy, a 56% increase at constant exchange rates over 2021. Much of that growth can be attributed to Farxiga's expansion into new settings, with approval for heart failure with reduced ejection fraction in May 2020 and for chronic kidney disease … Farxiga won FDA approval for adults with HFrEF in May 2020, which helped to drive its third-quarter sales up by a third to $525 million.
